Financial Performance Q1 FY27

  • Revenue from Operations: ₹756 crore, up 37% YoY from ₹551 crore in Q1 FY26
  • EBITDA: ₹111 crore, up 60.7% YoY from ₹69.5 crore in Q1 FY26
  • EBITDA Margin: 14.6% compared to 12.4% in Q1 FY26
  • PAT: ₹64.5 crore, up 89.9% YoY from ₹34 crore in Q1 FY26
  • PAT Margin: 8.4% compared to 6.1% in Q1 FY26
  • Export Contribution: 28.5% of revenue compared to 24.4% in same quarter last year

Operational Highlights

Pharmaceutical Division:

  • Strong demand across key products including paracetamol, pantoprazole, metformin, fenofibrate, and clopidogrel
  • Non-ibuprofen products contributed 43% of pharmaceutical revenue compared to 36% in Q1 FY26
  • Non-ibuprofen revenue grew 67% year-on-year
  • Most assets operating at 80-95% capacity utilization
  • Paracetamol capacity tripled to 10,800 MTPA, currently operating at 55% utilization, expected to reach 70% by end of FY27

Chemical Division:

  • Strong performance supported by improved realizations, efficient raw material procurement, higher exports, and operational efficiencies
  • Capacity enhancement across key product lines
  • New product Triacetin introduced with production starting after May 2026

Regulatory Approvals and Market Expansion

  • NMPA approval for clopidogrel in China
  • US FDA approval for five products with 2-3 more products lined up as formulators file ANDAs
  • CEP approval available for all products
  • Targeting different regulated markets including China

Guidance and Outlook

FY27 Guidance:

  • 15-20% revenue growth
  • EBITDA margin in range of 14-15%
  • Export contribution approximately 25-30% of revenue

Long-term Targets:

  • Expect non-ibuprofen segment to contribute 50-55% of API segment by FY29
  • Targeting 15-20% revenue growth and 15-17% EBITDA margin in FY28 (subject to market conditions)

Capital Expenditure

  • Annual capex of approximately ₹200 crores
  • 60% directed towards expansion and new products
  • 40% for infrastructure improvements and cost reduction
  • 101-acre land parcel available for future expansion (not expected to be utilized in FY27)

Raw Material Environment

  • Ethyl acetate and acetic anhydride prices increased substantially in March due to U.S.-Iran war
  • Prices have stabilized and are not on upward trend for the past month
  • Company expects delta between raw material and finished product prices to remain constant

R&D Investment

  • ₹26 crores invested in R&D during FY26
  • Funds allocated for purchasing new analytical equipment (XRD, LCMS, GCMS machines)
  • Focus on analyzing impurity profiles at stringent levels

Product Specific Details

  • Triacetin: Revenue potential of approximately ₹120 crores per year at 6,000 MTPA capacity
  • Paracetamol: Currently contributing significantly to non-ibu portfolio with growing export traction
  • Key Growth Drivers: Paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate, levetiracetam

Management Commentary

The strong performance was attributed to higher operating leverage, better capacity utilization, improved product mix, operational efficiencies, and increased export realizations. The company emphasized its strategy to build IOL as a diversified and integrated API platform with multiple products contributing to growth.